In 2011, Julphar’s sales exceeded AED 1 billion, an 11.3% increase over 2010. Julphar began producing biosimilars in 2012 and established a new division, Julphar Diabetes Solutions, which became the only company in the Middle East and North Africa to locally produce recombinant DNA (r-DNA), the raw material used in insulin production.

Julphar opened its first facility on the African continent with the opening of Julphar Ethiopia in 2013. The launch of Julphar Bangladesh took place two years later in 2015, coinciding with the launch of  the company’s consumer division, Julphar Life.

In 2017, Julphar acquired the IV fluid company Gulf Inject and officially opened a factory in Saudi Arabia in collaboration with  local partner Cigalah Group. In 2018, Julphar signed an agreement with the Ministry of Health (United Arab Emirates) to ensure the availability of critical medical supplies in emergency situations. In 2018, Julphar, together with its partner Merck and Co, won the Professional Association of Strategic Alliances Award, becoming the first pharmaceutical company in the Middle East and Africa to win such an award. The company also won the Frost and Sullivan 2018 Best Emerging GCC Pharmaceutical  Company Award.